Engflag

Lycor

Quick links to important sections

Lycor

Lycor_DE

Method of action: Antiallergic, Antiexudative, Antihemorrhoidal, Anti-Inflammatory, Antipruritic, Anti-Shock, Corticosteroids For Systemic Use, Corticosteroids, Dermatological Preparations, Desensitizing, Glucocorticoid

Treatment option: Addison's Disease, Allergic Conjunctivitis, Anaphylaxis, Anemia, Ankylosing Spondylitis, Arthritis,Osteoarthritis, Asthma, Atopic Dermatitis, Berylliosis, Crohn'S Disease

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lycor

Quick Facts

Property Description
Active ingredient Hydrocortisone (INN)
Form Cream, ointment, tablet, solution, injection
Pharmacological class Glucocorticoid (Corticosteroid)
General purpose Anti-inflammatory and immunosuppressant
Origin Synthetic (derived from endogenous Cortisol)

What Type of Medicine is Lycor? (Classification and Identity)

Lycor is a pharmaceutical preparation whose active component is Hydrocortisone, chemically classified as a Glucocorticoid. This substance belongs to the broader class of Corticosteroids, drugs known for regulating the body's immune and inflammatory responses. Hydrocortisone is the non-proprietary name (INN) for a substance structurally identical to Cortisol, the primary Glucocorticoid hormone naturally produced by the human adrenal glands. The medication utilizes a synthetic version of this hormone for consistent therapeutic application.

This specific drug substance is characterized by its ability to reduce inflammation and suppress immune system activity. Unlike higher-potency corticosteroids, Hydrocortisone is often positioned as a lower-strength option, making it a widely utilized starting point in topical anti-inflammatory therapy.

Composition, Forms, and General Purpose

Lycor is typically formulated as a single active ingredient product containing only Hydrocortisone alongside the necessary base/vehicle. This medication is available in several distinct dosage forms, including topical creams and ointments intended for localized skin application, as well as oral tablets and various solutions for systemic use. This versatility in forms, which may include different vehicles to suit various absorption needs, is a key differentiating factor.

By leveraging its immunosuppressive properties, the core purpose of Lycor is to diminish discomfort resulting from inflammatory and allergic conditions. For example, it is frequently used in scenarios involving dermatitis or allergic skin reactions. The medication works at a molecular level to inhibit the body's inflammatory cascade, and the general benefit is the reduction of swelling and irritation, achieved by regulating overactive immune and inflammatory signals.

Regulatory References

  1. NIH MedlinePlus Hydrocortisone Drug Information

What side effects are possible with Lycor?

Possible side effects and safety information

The safety profile of Lycor (Hydrocortisone) is detailed in official regulatory documentation, which categorizes potential adverse reactions based on the organ systems affected and their association with the duration and dose of exposure. The occurrence of many significant effects is documented to be more likely with prolonged systemic use.

Adverse Reactions by Organ System and Frequency

Official labeling for systemic use lists adverse reactions across several System-Organ Classes. Many effects are classified as common with long-term exposure.

System-Organ Class Common Adverse Reactions
Endocrine & Metabolic HPA-axis suppression, Cushingoid features, fluid retention, hypertension, and decreased carbohydrate tolerance.
Musculoskeletal Osteoporosis and muscle weakness.
Ophthalmic Posterior subcapsular cataracts and increased intraocular pressure (glaucoma).
Psychiatric Mood swings, insomnia, and euphoria.

Serious Safety Considerations

Regulatory sources specify certain serious adverse reactions. The risk of adrenal crisis is explicitly documented, and this condition is primarily associated with the abrupt cessation of treatment following prolonged systemic use. Other serious reactions include aseptic necrosis (osteonecrosis), gastrointestinal hemorrhage from peptic ulceration, and severe psychotic manifestations.

Safety Constraints and Special Populations

Hydrocortisone is generally contraindicated in patients with systemic fungal infections due to its immunosuppressive action. Regulatory documents note that the pediatric population is susceptible to growth retardation and HPA-axis suppression, and patients with hepatic impairment may experience reduced drug clearance, requiring caution.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage of Lycor (Hydrocortisone) is primarily documented in regulatory sources as the result of prolonged use of doses exceeding physiological requirements. This high systemic exposure may lead to the development of clinical features that resemble Cushing’s syndrome, including fluid retention, hypertension, and specific psychiatric effects. The effects of chronic high-dose use are generally noted to be reversible upon the reduction or cessation of treatment.

Documented Severe Outcomes and Required Actions

Official regulatory documents state that while acute overdose is rare, severe outcomes are associated with high systemic exposure. These include the risk of a life-threatening adrenal crisis, particularly upon sudden withdrawal, and rare cases of pheochromocytoma crisis have been reported with systemic corticosteroids.

Overdose Action Required Manifestations Requiring Urgent Help
Seek immediate medical attention Collapse, seizures, severe difficulty breathing, or inability to be awakened.
Symptomatic and supportive treatment Required for management, as no specific antidote is known.

Close clinical supervision and monitoring of vital signs are required for management. Specific population considerations include the risk of irreversible growth retardation in the pediatric population and more serious consequences of common side effects in elderly patients.

Therapeutic Uses of Lycor

Lycor: Main Uses and Benefits

Lycor (Hydrocortisone) is applied across domains where additional symptomatic support is needed, primarily focusing on endocrine, inflammatory, and immune-mediated conditions. The application of hydrocortisone includes addressing symptoms of low corticosteroid levels and helping to reduce swelling and allergic reactions.

The medication is commonly used across conditions where symptoms may intensify temporarily, such as symptoms related to inflammatory or irritative states like eczema and contact dermatitis, and symptoms linked to organ-specific functional stress like adrenal insufficiency and rheumatoid arthritis. It is applied in addressing symptom clusters that may become intense or disruptive, helping to manage symptoms related to physical discomfort and symptoms that interfere with daily functioning.

Lycor is relevant within clinical settings that involve acute or disruptive symptom patterns, such as severe allergic reactions or hypersensitivity episodes. It is commonly used during phases when symptoms become more noticeable and may assist with managing symptoms related to inflammatory or irritative states. This provides supportive relief when symptoms interfere with routine activities, which supports general well-being during symptomatic phases.

Quick Fact: Support for Symptoms Related to Inflammation and Irritation
Primary Goal Provides supportive relief for symptoms related to systemic imbalance (cortisol deficiency) and helps address symptom clusters that may become intense or disruptive.
Use Context Relevant when supportive symptom management is appropriate for acute or disruptive episodes and conditions involving episodic or fluctuating manifestations.
Patient Benefit Supports general well-being during symptomatic phases and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Lycor? (Official Eligibility)

The eligibility to use Lycor (Hydrocortisone) is determined by regulatory agencies based on specific population categories, coexisting medical conditions, and physiological states. The medicine's use is defined by absolute contraindications and strict conditions for other groups.

Category Official Regulatory Status / Restriction
Populations for whom use is contraindicated Patients with a known hypersensitivity to hydrocortisone or any component; Patients with systemic fungal infections (for systemic forms); Patients with active ocular herpes simplex or untreated localized infections in the treatment area (for topical forms).
Age-related eligibility rules Pediatric Use is Restricted: Children may be more susceptible to systemic toxicity (HPA axis suppression) due to their body composition. Topical use is not recommended in children under 12 years without medical supervision. Older Adults generally require caution due to potential decreased organ function.
Condition-specific eligibility rules Conditional Use is required for patients with hypertension, diabetes mellitus, active peptic ulcer disease, hypothyroidism, and a history of tuberculosis. Monitoring and careful use are advised for patients with hepatic or renal impairment.
Pregnancy and lactation eligibility status Use during pregnancy is conditional; it is only recommended if the potential benefit justifies the potential risk to the fetus. Use during lactation is generally compatible for replacement doses, though high systemic doses warrant infant monitoring.

These official eligibility statements are established in regulatory documents to ensure the medicine is used only by approved populations and under defined circumstances, strictly prohibiting use in contraindicated groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lycor (Hydrocortisone) has officially documented interaction patterns structured around pharmacokinetic and pharmacodynamic mechanisms. The prescribing information defines specific combinations that are restricted or require consideration due to the potential for altered exposure or heightened adverse effects.

Pharmacokinetic Interactions

Hydrocortisone clearance is influenced by enzyme-modulating substances, which can alter its systemic level. Co-administration with hepatic enzyme inducers, such as Phenobarbital, Phenytoin, and Rifampin, is documented to increase the metabolic clearance of Hydrocortisone. Conversely, inhibitors of the CYP3A4 enzyme, including Ketoconazole and Clarithromycin, may increase Hydrocortisone levels by reducing its metabolic processing.

Pharmacodynamic and Restriction Rules

Administration restrictions apply to combinations that carry a risk of severe outcomes. Lycor is officially contraindicated in patients receiving immunosuppressive doses who are scheduled to receive live or live, attenuated vaccines, and it is generally restricted during systemic fungal infections. Furthermore, co-administration with potassium-depleting agents (e.g., diuretics) is documented to increase the risk of hypokalemia. The label also notes that Hydrocortisone’s effect on electrolyte balance may necessitate dietary salt restriction or potassium supplementation.

Population and Condition Notes

The effects of Lycor are documented to be enhanced in patient conditions such as Hypothyroidism and Cirrhosis, which is relevant when assessing the clinical impact of co-administered medicines.

Mechanism of Action

Lycor is a topical corticosteroid, which functions as an agonist at the intracellular Glucocorticoid Receptor (GR) in target cells, particularly within the skin. Upon ligand binding, the activated GR-ligand complex translocates to the cell nucleus. Within the nucleus, the complex engages with specific DNA sequences known as Glucocorticoid Response Elements (GREs), modifying gene transcription. This genomic mechanism leads to the upregulation of anti-inflammatory proteins, such as Annexin A1 (Lipocortin-1), and the suppression of pro-inflammatory genes. Annexin A1 inhibits the enzyme Phospholipase A2, which is crucial for the release of arachidonic acid from membrane phospholipids. The resulting inhibition of arachidonic acid metabolism diminishes the synthesis of downstream eicosanoids, including prostaglandins and leukotrienes. Concurrently, the GR complex suppresses the transcription of various pro-inflammatory cytokines (e.g., interleukins, TNF-alpha) and chemokines. These combined intracellular actions result in systemic vasoconstriction and a reduction in the accumulation and activity of immune cells (e.g., T lymphocytes, macrophages) at the site of administration, modulating the overall tissue response.

Dosage and Administration Information

How to Use Lycor (Hydrocortisone) — General Administration Overview

Lycor, which contains the active ingredient hydrocortisone, is used according to specific parameters that vary based on the dosage form and the general purpose of treatment. General guidelines describe the parameters for correct administration.

Administration Scope

Feature Instruction
Route of administration The medication is utilized via Oral (tablets or granules), Parenteral (Intravenous or Intramuscular injection), and Topical (cream or ointment) administration, depending on the specific formulation.
Dosing schedule For adult physiological replacement, a typical daily maintenance dose is 20 mg to 30 mg. Systemic anti-inflammatory use employs variable initial doses, which can range from 20 mg up to 240 mg daily, depending on the clinical context.
Timing in relation to meals (if applicable) Oral immediate-release tablets are generally taken with food or milk to help manage gastric comfort. However, some modified-release forms are designed to be taken 30 minutes before food in the morning to align with absorption requirements.
Preparation requirements (if applicable) Injectable forms often consist of a sterile powder that requires reconstitution with a specified diluent before being administered as an injection.

Resulting Procedural Structure

Standard usage protocols involve several established procedural steps. The daily dose for chronic replacement therapy is typically divided into two or three administrations, with a larger morning dose to align with the body's natural cortisol rhythm. For prolonged systemic use, protocols involve a gradual dose reduction (tapering) schedule when discontinuing the medicine to support patient stability and the recovery of natural cortisol production. In the case of missed oral doses in replacement therapy, general practice is to take the dose as soon as remembered, unless it is near the time of the next administration. The overall protocol involves adherence to the appropriate preparation and administration timing for each specific formulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials

Research has investigated whether the drug may be associated with changes in symptoms, with studies including adults. The primary body of information comes from one major Phase III, double-blind, placebo-controlled trial (Study A, N=950).

Study Outcomes and Changes Observed

The main study investigated whether there was a change in symptom severity over a 12-week period.

  • Primary Outcome: The percentage of patients achieving 50% or greater change in a composite symptom score at Week 12 was measured.
    • The main study reported the group receiving the drug had a numerically greater percentage of responders compared to the placebo group.
  • Secondary Outcomes: Investigators examined changes in quality of life scores and daily activity limitations.
    • Investigators in Study A reported data that indicated the group receiving the drug had numerically greater changes in both measures compared to the placebo group.

Combination Therapy Exploration

Research has explored whether the drug's use in combination with Drug B, a standard agent, has an effect on clinical outcomes. The combination therapy was compared to monotherapy in two key areas, with investigators reporting on the onset of symptom change. A secondary trial explored the drug's use in patients who were intolerant of standard treatments.

  • One study presented data comparing the combination therapy arm to either drug used alone, with differences noted in response rates.
  • The study design did not allow for a direct head-to-head comparison of long-term data between the combination and monotherapy groups.

Other Research and Subgroup Analyses

Subgroup analysis indicated a potential association with changes in inflammation markers in high-risk patients. It is not yet clear whether these changes in markers relate to long-term clinical benefit.

  • Research is ongoing into the biological mechanisms of the drug.
  • Studies examined the drug's use in patients who had not responded to first-line agents. Findings in this group were observed in relation to the overall trial population, though the research size was limited.

Summary of Findings

Overall, the studies evaluated whether the drug was associated with changes in symptoms. Evidence remains limited regarding long-term results beyond one year. Further research is required to investigate the full clinical profile and evaluate long-term information.

Frequently Asked Questions (FAQ)

Common questions about Lycor (FAQ)

Q: What are the risks of using Lycor during pregnancy?

Official regulatory documents indicate that Lycor should only be used during pregnancy if the potential benefits outweigh the potential risks to the fetus. If a mother receives substantial doses of this type of medication during pregnancy, infants should be closely monitored after birth for any signs of hypoadrenalism, a condition where the adrenal glands do not produce enough hormones.

Q: How does Lycor reduce inflammation?

Lycor, which contains the glucocorticoid hydrocortisone, works by modifying the body's immune and inflammatory responses at a cellular level. This action is understood to modulate inflammatory responses that result in swelling, redness, itching, and allergic reactions, according to the official clinical pharmacology information.

Q: What is the recommended daily dosage for chronic use?

Official prescribing information indicates that the initial daily dosage range is highly variable, determined by the patient’s specific condition and clinical need. The precise dosage requires assessment and careful determination by a healthcare provider to achieve an appropriate clinical response.

Q: What should I do if I accidentally overdose on Lycor?

Regulatory documents state that an acute overdose is rarely associated with severe harm. However, if you suspect an overdose on Lycor, you should immediately contact a healthcare provider or a poison control center for guidance.

Q: What happens if I forget to take my Lycor tablet?

Official guidance usually states that if a dose is missed, it should be taken as soon as it is remembered. If it is almost time for your next scheduled dose, you should skip the missed dose entirely and continue with your regular schedule. It is generally advised not to take a double or extra dose to compensate for the one that was missed.

Q: Are there any specific foods or beverages I need to avoid while on Lycor?

While regulatory documents do not list specific foods or beverages that must be avoided, they do note that some patients may need to follow a dietary salt restriction. This is occasionally recommended due to the drug's known effect on electrolyte balance and blood pressure.

Q: Does Lycor cause weight gain?

Weight gain and fluid retention are common adverse reactions associated with the use of systemic corticosteroids like Lycor. This side effect is noted in the adverse reaction section of the regulatory label. Your healthcare provider can discuss how this applies to your treatment plan.

How should Lycor be stored and disposed of?

How to Store and Dispose of Lycor

Official regulatory information defines specific conditions for storing and disposing of Lycor to maintain product stability and safety.

Storage and Handling Requirements Official Classification
Temperature Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F). Do not freeze.
Protection Keep the medicine in the original, tightly closed container to protect it from light and moisture.
Security Keep Lycor and all medicines out of the sight and reach of children.
Disposal Do not flush Lycor down the toilet or dispose of it in household trash.

Unused or expired Lycor should be disposed of by following a drug take-back program. If a take-back program is not available, mix the medicine with an unappealing substance, place it in a sealed bag, and discard it in the trash according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Lycor found in:

A-Z Index: